Introduction
Immunosuppressive microenvironment of HCC
Cell type | Markers | Properties in HCC | Reference |
---|---|---|---|
TAMs | OPN, C1QA, THBS1, APOE, SLC40A1, GPNMB | Related with reduced CD8 + T cell infiltration in TME and poor prognosis. | |
TANs | MMP8, APOA2, CD74, IFIT1, SPP1, CCL4 | Inhibited the cytotoxicity of CD8 + T cells by elevating PD-L1 expression. | [32] |
cDCs | CLEC9A, XCR1, CADM1(cDC1); CD1C, FCER1A, CLEC10A (cDC2) | Primarily responsible for antigen presentation. | [10] |
pDCs | BDCA2, ILT7 | Associated with infiltration of Tregs and poor prognosis of HCCs. | [38] |
Migratory DCs | LAMP3, CD80, CD83, CCR7, CCL19, CCL21 | Migratory DCs exhibited migratory capacity and a strong correlation with TEX. | [10] |
NK cells | CD56, CD16 | The higher number of NK cells correlated with a positive prognosis in HCC. | [50] |
Helper ILCs | CD127 | Functional heterogeneity. | [51] |
Activated CD8 + T cells | CD8, GZMB | Associated with a favorable prognosis in HCC. | [66] |
TEX | CD8, PD-1, TIM-3 | Enrichment of TEX was linked to poor PFS and OS. | |
TRM | CD69, CD103 | Associated with a better prognosis and response to immunotherapy. | [64] |
Tregs | CD4, FOXP3, CTLA-4 | Tregs mediate T cell exhaustion and are associated with poor prognosis. | |
Th | IFN-γ, IL-2 (Th1); IL-4, IL-5 (Th2); IL-17 (Th17) | Different Th subtypes exert positive or negative effects on the immune response. | [75] |
B cells | CD19, CD20 | Main constituent of TLS which correlates with a favorable prognosis. | [84] |
CAFs | α-SMA, COL1A2, COL1A1 | Mediated immune evasion by direct interactions, secretion of cytokines, and ECM. | [97] |
ECs | PLPP3, IGFBP3, PLVAP | Interacted with TAMs and CAFs to attenuate the response of immunotherapy. | [52] |
Tumor-associated macrophages (TAMs)
Tumor-associated neutrophils (TANs)
Dendritic cells
Innate lymphoid cells
T cells
B cells
Non-hematopoietic stromal cells
Platelets
The heterogeneity of TME and response to immunotherapy
Clinically established immunotherapies
ICIs
Study | Drug | Start | N | mOS | mPFS |
---|---|---|---|---|---|
IMbrave150 [120] | Atezolizumab + bevacizumab vs. sorafenib | 2018 | 558 | 19.2 vs. 13.4 mo (HR 0.66; 95% CI 0.52–0.85) | 6.8 vs. 4.3 mo (HR 0.65; 95% CI 0.53–0.81) |
ORIENT-32 [124] | Sintilimab + bevacizumab biosimilar vs. sorafenib | 2019 | 595 | not reached vs. 10.4 mo (HR 0.57; 95% CI 0.43–0.75) | 4.6 vs. 2.8 mo (HR 0.56; 95% CI 0.46–0.70) |
LEAP-002 [133] | Lenvatinib + pembrolizumab vs. lenvatinib | 2018 | 794 | 21.2 vs. 19.0 mo (HR 0.84; 95% CI 0.71-1.00) | 8.2 vs. 8.0 mo (HR 0.87; 95% CI 0.73–1.02) |
COSMIC-312 [134] | Cabozantinib + atezolizumab vs. sorafenib | 2018 | 837 | 15.4 vs. 15.5 mo (HR 0.90; 95% CI 0.69–1.18) | 6.8 vs. 4.2 mo (HR 0.63; 95% CI 0.44–0.91) |
CARES-310 [136] | Camrelizumab + rivoceranib vs. sorafenib | 2019 | 543 | 22.1 vs. 15.2 mo (HR 0.62; 95% CI 0.49–0.80) | 5.6 vs. 3.7 mo (HR 0.52; 95% CI 0.41–0.65) |
HIMALAYA [138] | Tremelimumab + durvalumab vs. durvalumab vs. sorafenib | 2017 | 1324 | 16.4 vs. 16.6 vs. 13.8 mo (HR 0.78; 95% CI 0.65–0.93) | 3.78 vs. 3.65 vs. 4.07 mo |
Combination of ICIs with anti-VEGF agents
Combination of ICIs with TKIs
Combination of different ICIs
The roles of immunotherapy-based perioperative treatment in HCC
Study | Treatment setting | Drug | Phase | n | Primary endpoint | Efficacy |
---|---|---|---|---|---|---|
IMbrave050 [128] | Adjuvant | Atezolizumab + bevacizumab vs. placebo | III | 668 | RFS | Improved RFS HR = 0.72 (95% CI 0.53–0.98; p = 0.012) |
Checkmate 9DX [142] | Adjuvant | Nivolumab vs. placebo | III | 545 | RFS | NA |
EMERALD-2 [143] | Adjuvant | Durvalumab ± bevacizumab vs. placebo | III | 908 | RFS | NA |
KEYNOTE-937 [144] | Adjuvant | Pembrolizumab vs. placebo | III | 950 | RFS/OS | NA |
JUPITER 04 | Adjuvant | Toripalimab vs. placebo | II/III | 402 | RFS | NA |
NCT04639180 | Adjuvant | Camrelizumab + Rivoceranib vs. active surveillance | III | 687 | RFS | NA |
Wang K, et al. [145] | Adjuvant | Sintilimab vs. active surveillance | II | 198 | RFS | 27.7 vs. 15.5 mo; HR = 0.534 (95% CI 0.360–0.792; p = 0.002) |
NCT05613478 | Neoadjuvant | Camrelizumab + apatinib + TACE | III | 130 | RFS | NA |
NCT05250843 | Neoadjuvant | Sintilimab + lenvatinib + TACE/HAIC | II/III | 90 | RFS | NA |
HCC-009 [146] | Neoadjuvant | Camrelizumab + apatinib | II | 20 | MPR | ORR = 16.7% 1-year RFS = 53.85% |
NCT03222076 [147] | Neoadjuvant/ adjuvant | Nivolumab ± ipilimumab | II | 30 | AEs | mRFS = 19.53 vs. 9.4mo |
NIVOLEP | Neoadjuvant | Nivolumab | II | 43 | RFS | NA |
NCT04615143 | Neoadjuvant | Tislelizumab ± levatinib | II | 80 | DFS | NA |
NCT03867370 | Neoadjuvant | Toripalimab ± levatinib | II | 40 | MPR | NA |
NCT05056337 | Conversion | Toripalimab + Lenvatinib + TACE | III | 220 | ORR | NA |
LEN-TAC | Conversion | Camrelizumab + Lenvatinib + TACE | III | 168 | Conversion rate/OS | NA |
NCT04042805 [151] | Conversion | Sintilimab + lenvatinib | II | 36 | ORR | ORR = 35% Conversion rate = 27% |
NCT04843943 [152] | Conversion | Sintilimab + bevacizumab | II | 30 | AEs/EFS | ORR = 23.3% Conversion rate = 43% |
NCT05029973 [153] | Conversion | Sintilimab + bevacizumab + HAIC | II | 30 | ORR | ORR = 66.7% Conversion rate = 47% |
The novel ways to enhance the response of HCC to ICIs
Emerging immunotherapies
Therapies | Agents | Descriptions | Trial | Clinical results | Reference |
---|---|---|---|---|---|
Adoptive cell therapy | CAR-GPC3 T | Autologous T cells bearing CAR that can recognize GPC3 | NCT02395250 (phase I) NCT03146234 (phase I) | PR in 2 out of 13 patients | [166] |
GPC3-7 × 19 CAR-T | CAR-GPC3 T cells secreting IL-7 and CCL19 | NCT03198546 (phase I) | CR in one patient with advanced HCC | [170] | |
AFP TCR-T | Autologous T Cells expressing TCRs specific for AFP | NCT03132792 (phase I) | Achieved 1 CR among 4 patients without significant liver toxicity | [164] | |
HBV-specific TCR-T | Autologous T Cells expressing TCRs specific for HBV | NCT02719782 (phase I) NCT03899415 (phase I) | Confirmed the safety and tolerability of HBV-specific TCR-T cell therapy | ||
Neoantigen vaccines | Neoantigen peptides | Long peptides of predicted neoantigens derived from mutations | ChiCTR1900020990 | Achieved an RFS of 7.4 months | [190] |
GNOS-PV02 | Personalized DNA neoantigen vaccine | NCT04251117 (phase I/II) | Achieved 3 PR and 5 SD among 12 patients | [192] | |
Neoantigen-loaded DC vaccines | DCs loaded with neoantigen peptides | NCT03067493 (phase II) NCT04912765 (phase II) | Achieved a longer DFS in patients who developed immune responses | [195] | |
mRNA vaccine | Personalized mRNA neoantigen vaccine | NCT05761717 | No results posted | ||
Oncolytic viruses | T-Vec | Engineered low-toxicity HSV expressing GM-CSF | NCT02509507 (phase Ib/II) | No fatal AE was observed | [201] |
JX-594 | Genetically modified VV expressing GM-CSF and β-galactosidase | NCT01387555 (phase IIb) NCT02562755 (phase III) | Fail to provide benefits for HCC patients | [205] | |
H101 | Type 5 adenovirus been modified to delete the E1B55K protein | NCT05675462 (phase I) | No results posted | ||
Bispecific antibodies | GPC3-CD3 BsAb | Redirect T cells to HCC cells by engaging CD3 on T cells and GPC3 | NCT02748837 (phase I) | No results posted | [217] |
PD-1-CTLA-4 BsAb | Synergistically target two immune checkpoints on immune cells | NCT04728321 (phase II) NCT04444167 (phase Ib/II) NCT05773105 (phase I/II) NCT05925413 (phase II) | No results posted |